Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes

Robert R Henry, Julio Rosenstock, Douglas K Logan, Thomas R Alessi, Kenneth Luskey, Michelle A Baron, Robert R Henry, Julio Rosenstock, Douglas K Logan, Thomas R Alessi, Kenneth Luskey, Michelle A Baron

Abstract

Objective: To evaluate ITCA 650, a continuous subcutaneous miniature osmotic pump delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in subjects with type 2 diabetes.

Research design and methods: We conducted a randomized, two-stage, 24-week, open-label, phase 2 study in type 2 diabetes inadequately controlled with metformin. Stage I: 155 subjects were randomized to 20 or 40 μg/day of ITCA 650 or Ex-BID 5 → 10 μg. Stage II: 131 subjects were rerandomized to 20, 40, 60, or 80 μg/day of ITCA 650. Change from baseline for HbA1c, weight, and fasting plasma glucose were evaluated at weeks 12 and 24.

Results: HbA1c was significantly lower in all groups after 12 and 24 weeks. Stage I: mean change in HbA1c from a mean baseline of 7.9-8.0% was -0.98, -0.95, and -0.72% for the 20 and 40 μg/day ITCA 650 and Ex-BID groups, respectively, with 63, 65, and 50% of subjects achieving HbA1c levels ≤ 7% (P < 0.05). Stage II: significant (P < 0.05) reductions in HbA1c (≈ 1.4% from baseline) were achieved with 60 and 80 μg/day ITCA 650, and 86 and 78% of subjects achieved HbA1c ≤ 7% at 24 weeks; respectively. Weight was reduced by 2.8-3.7 kg (P < 0.05) at 24 weeks in all except the 20 → 20 μg/day group. ITCA 650 was well tolerated; nausea was lower and transient with 20 μg/day relative to Ex-BID; and 60 μg/day had the best profile of tolerability and HbA1c lowering.

Conclusions: ITCA 650 significantly reduced HbA1c and weight and was well tolerated. The 20 → 60 μg/day regimen was considered the best dose for further examination in phase 3.

Trial registration: ClinicalTrials.gov NCT00943917.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194–206
    1. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44–57
    1. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009;160:909–917
    1. American Diabetes Association Standards of medical care in diabetes—2012. Diabetes Care 2012;35(Suppl. 1):S11–S63
    1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–559
    1. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231–238
    1. Jose B, Tahrani AA, Piya MK, Barnett AH. Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Prefer Adherence 2010;4:313–324
    1. Bydureon [package insert]. San Diego, CA, Amylin Pharmaceuticals, 2012
    1. Rohloff CM, Alessi TR, Yang B, Dahms J, Carr JP, Lautenbach SD. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Tech 2008;2:461–467
    1. Yang B, Negulescu C, D’vaz R, et al. Stability of ITCA 650 for continuous subcutaneous delivery of exenatide at body temperature for 12 months. Abstract presented at the Ninth Annual Diabetes Technology Meeting, 5–7 November 2009, San Francisco, California
    1. Luskey K, McNally J, Dahms J, Alessi T. Continuous subcutaneous delivery of exenatide via ITCA 650 lowers plasma glucose, HbA1c and reduces weight in a 28-day phase 1b study in type 2 diabetes. Abstract presented at the Ninth Annual Diabetes Technology Meeting, 5–7 November 2009, San Francisco, California
    1. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010;10:20.
    1. Drucker DJ, Buse JB, Taylor K, et al. DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–1250
    1. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9.
    1. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–1310
    1. Edavalath M, Stephens JW. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence 2010;4:61–68
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497
    1. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314–322
    1. Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med 2009;32:278–284
    1. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240–245
    1. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009;35:1014–1022
    1. Kuritzky L. Overcoming barriers to insulin replacement. J Fam Pract 2009;58(Suppl. 8):S25–S31
    1. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl. 5A):27S–34S
    1. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78–83
    1. Donnelly LA, Morris AD, Evans JM, DARTS/MEMO collaboration Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345–350
    1. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777–786
    1. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl. 1):25–32
    1. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011;27(Suppl. 3):13–20

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅